UNSPSC 41131714: Hemoglobin a2assay

In this classification a hemoglobin A2 assay is a device used to determine the hemoglobin A2 content of human blood. The measurement of hemoglobin A2 is used in the diagnosis of the thalassemias (hereditary hemolytic anemias characterized by decreased synthesis of one or more types of hemoglobin polypeptide chains) US FDA regulates Hemoglobin a2assay under 21 CFR 864.7400 and under FDA product code LGL.

UNSPSC 41131714 Hemoglobin A2 Assay, a Commodity code, does not align with the recent state and local contract opportunities posted under this classification. The code nominally describes a single diagnostic laboratory test — hemoglobin A2 measurement — used primarily in sickle cell disease and thalassemia screening; however, the recent opportunities tagged to this code center on offender drug testing, employment screening physicals, breath alcohol devices, naloxone procurement, and forensic drug standards. Of these, only the urinalysis and offender specimen collection solicitations involve laboratory-based drug-screening services with any proximity to clinical laboratory assay work, yet neither addresses hemoglobin A2 testing specifically. The mismatch suggests either miscoding by issuing bodies or a data artifact. Across the opportunities present, state and local buyers are procuring broad employment and forensic drug-testing services, medical screening coordination, and breath alcohol devices — work that falls outside the narrow scope of a single hemoglobin assay commodity.

Recent activity appears concentrated in Florida and Texas counties with scattered activity in Oregon and Nevada. Collin County, Texas issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated $600,000 annually) requiring immunoassay screening with confirmatory LC/MS/MS or GC/MS testing at two Plano and McKinney sites; Seminole County, Florida posted IFB 60459723LAS for naloxone and drug deactivation systems (due July 26, 2023); Benton County, Oregon requested proposals for urinalysis testing supporting a family treatment court (RFP due July 7, 2026); and Clay County and Collier County, Florida each issued bids and RFPs for employment physicals and drug testing. City Colleges of Chicago released RFP MWJ2603 for employment screening and pre-employment drug testing (proposals due March 30, 2026) requiring SaaS integration with Oracle Taleo and MBE/WBE set-asides of 25% and 7% respectively. The State of Nevada Department of Public Safety posted two separate IFBs for Intoxilyzer 9000 breath alcohol devices (due February 12 and 17, 2026). No hemoglobin A2 assay-specific opportunities appear in the recent posting block, indicating minimal or no relevant state and local procurement activity under this code.